Glenn Harvey
Illustrator
From this contributor
How long-read sequencing will transform neuroscience
New technology that delivers much more than a simple DNA sequence could have a major impact on brain research, enabling researchers to study transcript diversity, imprinting and more.
![A figure walks along a long road with a gene-sequence-like pattern.](https://www.thetransmitter.org/wp-content/uploads/2023/11/1200_longread-1-1024x683.webp)
How long-read sequencing will transform neuroscience
What kind of autism research should we do, and where should we do it?
Researchers at INSAR 2023 need to discuss these questions and remember that the purpose of research may be different for different communities.
![Three people stand on a staircase and contemplate a maze-like array of paths in the sky before them.](https://www.thetransmitter.org/wp-content/uploads/2023/05/844-what-kind-of-autism-research.jpg)
What kind of autism research should we do, and where should we do it?
New measure characterizes gender diversity in study participants
The Gender Self-Report could help autism researchers include more gender-diverse people across a range of ages and neurotypes in their work.
![Illustration of a diverse group of bodies floating in space.](https://www.thetransmitter.org/wp-content/uploads/2023/04/844-lede-gender-diversity-study-participants-autism.jpg)
New measure characterizes gender diversity in study participants
Lessons from n-of-1 trials: A conversation with Joseph Gleeson
Some conditions are too rare for conventional drug trials, leading some scientists to test bespoke treatments in single participants. Gleeson discusses the merits — and limitations — of these tiny trials.
![Illustration of a single patient in a clinical trial sitting on a bed in a glitchy, imperfectly rendered room.](https://www.thetransmitter.org/wp-content/uploads/2023/03/844-gleeson-n-of-1-autism.jpg)
Lessons from n-of-1 trials: A conversation with Joseph Gleeson
Debut drug for Rett syndrome at edge of approval
The U.S. Food and Drug Administration plans to make an approval decision on the first-ever drug for girls and women with Rett syndrome by 12 March.
![Illustration of a gloved hand reaching down to place a pill bottle on a pedestal.](https://www.thetransmitter.org/wp-content/uploads/2023/03/844-enterprise-rett.jpg)
Debut drug for Rett syndrome at edge of approval
Explore more from The Transmitter
New connectomes fly beyond the brain
Researchers are mapping the neurons in Drosophila’s ventral nerve cord, where the central nervous system meets the rest of the body.
![Research image of neurons in the fly’s ventral nerve cord.](https://www.thetransmitter.org/wp-content/uploads/2024/07/lede-motormodules-1200-1024x692.webp)
New connectomes fly beyond the brain
Researchers are mapping the neurons in Drosophila’s ventral nerve cord, where the central nervous system meets the rest of the body.
Building an autism research registry: Q&A with Tony Charman
A purpose-built database of participants who have shared genomic and behavioral data could give clinical trials a boost, Charman says.
![Illustration of researchers talking to laypeople amidst strands of DNA.](https://www.thetransmitter.org/wp-content/uploads/2024/07/1200_Charman-1024x687.webp)
Building an autism research registry: Q&A with Tony Charman
A purpose-built database of participants who have shared genomic and behavioral data could give clinical trials a boost, Charman says.
Cerebellar circuit may convert expected pain relief into real thing
The newly identified circuit taps into the brain’s opioid system to provide a top-down form of pain relief.
![](https://www.thetransmitter.org/wp-content/uploads/2024/07/paincircuit-1200-1024x692.webp)
Cerebellar circuit may convert expected pain relief into real thing
The newly identified circuit taps into the brain’s opioid system to provide a top-down form of pain relief.